NCT04717700 - Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

August 1, 2025

Study Completion Date

June 1, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Selinexor 20 MG Oral Tablet

Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone

DRUG

Bortezomib Injection

Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone

DRUG

Lenalidomide capsule

Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone

DRUG

Dexamethasone Oral

Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone

Trial Locations (11)

North Estonia Medical Centre Foundation, Tallinn

Aalborg University Hospital, Aalborg

Sydvestjysk Sygehus Esbjerg, Esbjerg

Regionshospitalet Gødstrup, Gødstrup

Odense University Hospital, Odense

Haukeland University Hospital, Bergen

Førde Central Hospital, Førde

Kristiansund Hospital, Kristiansund

Oslo Universitets Hospital, Oslo

Stavanger University Hospital, Stavanger

St. Olavs University Hospital, Trondheim